破裂颅内动脉瘤血流导向治疗:采用标准化抗血栓治疗方案的单中心研究
该单中心回顾性研究纳入2015-2023年连续39例患者共40个急性破裂颅内动脉瘤,比较标准化抗血栓方案实施前后血流导向治疗的血栓栓塞与出血并发症及6个月mRS结局,发现两组并发症发生率无组间差异,作者认为亟需更多循证指南优化蛛网膜下腔出血后血流导向治疗的抗血栓策略。
要点
- 39例患者40个破裂动脉瘤接受血流导向治疗,69%为方案前组,31%为方案后组。
- 方案后组糖蛋白IIb/IIIa抑制剂使用(48% vs 100%)和早期双联抗血小板使用(44% vs 92%)均较方案前组升高。
- 缺血并发症方案前组37% vs 方案后组42%,出血并发症方案前组30% vs 方案后组33%,均无组间差异。
核心结论
- 实施标准化抗血栓方案后,急性破裂颅内动脉瘤血流导向治疗的缺血性或出血性并发症发生率无重大差异。
- 作者认为亟需更多循证指南以优化蛛网膜下腔出血背景下血流导向治疗后的抗血栓治疗。
研究设计与样本
- 单中心回顾性研究,纳入2015-2023年连续接受血流导向治疗的急性破裂颅内动脉瘤患者。
- 共39例患者、40个破裂颅内动脉瘤,分为方案实施前组(69%)和方案实施后组(31%)。
- 主要结局为出血性和缺血性并发症,次要结局为改良Rankin量表(mRS)评估的临床结局。
主要发现
- 患者平均年龄55岁,62%为女性,63%的动脉瘤位于后循环,92%的动脉瘤为非囊状,44%入院时分级差。
- 治疗方案差异包括糖蛋白IIb/IIIa抑制剂使用(方案前组48% vs 方案后组100%)和早期双联抗血小板使用(方案前组44% vs 方案后组92%)。
- 缺血并发症发生率方案前组37% vs 方案后组42%,出血并发症发生率方案前组30% vs 方案后组33%,均无组间差异。
- 动脉瘤再破裂方案前组3例(11%)vs 方案后组0例。
- 6个月时两组死亡率及mRS 0-2无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of antithrombotic medication following acute flow diversion for a ruptured intracranial aneurysm (IA) is challenging with no current guidelines. We investigated the incidence of treatment-related complications and patient outcomes after flow diversion for a ruptured IA before and after the implementation of a standardized antithrombotic medication protocol. METHODS: We conducted a single-center retrospective study including consecutive patients treated for acutely ruptured IAs with flow diversion during 2015-2023. We divided the patients into two groups: those treated before the implementation of the protocol (pre-protocol) and those treated after the implementation of the protocol (post-protocol). The primary outcomes were hemorrhagic and ischemic complications. A secondary outcome was clinical outcome using the modified Ranking Scale (mRS). RESULTS: Totally 39 patients with 40 ruptured IAs were treated with flow diversion (69% pre-protocol, 31% post-protocol). The patient mean age was 55 years, 62% were female, 63% of aneurysms were in the posterior circulation, 92% of aneurysms were non-saccular, and 44% were in poor grade on admission. Treatment differences included the use of glycoprotein IIb/IIIa inhibitors (pre-group 48% vs. post-group 100%), and the use of early dual antiplatelets (pre-group 44% vs. 92% post-group). The incidence of ischemic complications was 37% and 42% and the incidence of hemorrhagic complications was 30% and 33% in the pre- and post-groups, respectively, with no between-group differences. There were three (11%) aneurysm re-ruptures in the pre-group and none in the post-group. There were no differences in mortality or mRS 0-2 between the groups at 6 months. CONCLUSION: We found no major differences in the incidence of ischemic or hemorrhagic complications after the implementation of a standardized antithrombotic protocol for acute flow diversion for ruptured IAs. There is an urgent need for more evidence-based guidelines to optimize antithrombotic treatment after flow diversion in the setting of subarachnoid hemorrhage.
引用
- Rantamo A, Gallé C, Numminen J, et al. Flow diversion of ruptured intracranial aneurysms: a single-center study with a standardized antithrombotic treatment protocol. Acta Neurochir (Wien). 2024. PMID: 38467916. doi:10.1007/s00701-024-06029-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。